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Abstract:  Endothelial  cells  (ECs)  that  line  the  lumen  of  blood  vessels  are  important 
players in blood vessel formation, and EC migration is a key component of the angiogenic 
process. Thus, identification of genes that are specifically or preferentially expressed in 
vascular ECs and in-depth understanding of their biological functions may lead to discovery 
of  new  therapeutic  targets.  We  have  previously  reported  molecular  characterization  of 
human endothelial cell-specific molecule 2 (ECSM2)/endothelial cell-specific chemotaxis 
regulator  (ECSCR).  In the present  study, we cloned two  mouse  full-length  cDNAs  by  
RT-PCR,  which  encode  two  putative  ECSCR  isoform  precursors  with  considerable 
homology to the human ECSCR. Nucleotide sequence and exon-intron junction analyses 
suggested that they are alternative splicing variants (ECSCR isoform-1 and -2), differing 
OPEN ACCESS Int. J. Mol. Sci. 2012, 13  4921 
 
from each other in the first and second exons. Quantitative RT-PCR results revealed that 
isoform-2 is the predominant form, which was most abundant in heart, lung, and muscles, 
and  moderately  abundant  in  uterus  and  testis.  In  contrast,  the  expression  of  isoform-1 
seemed to be more enriched in testis. To further explore their potential cellular functions, 
we  expressed  GFP-  and  FLAG-tagged  ECSCR  isoforms,  respectively,  in  an  ECSCR 
deficient cell line (HEK293). Interestingly, the actual sizes of either ECSCR-GFP or -FLAG 
fusion proteins  detected by immunoblotting are much larger than their predicted sizes, 
suggesting that both isoforms are glycoproteins. Fluorescence microscopy revealed that 
both  ECSCR  isoforms  are  localized  at  the  cell  surface,  which  is  consistent  with  the 
structural prediction. Finally, we performed cell migration assays using mouse endothelial 
MS1 cells overexpressing GFP alone, isoform-1-GFP, and isoform-2-GFP, respectively. 
Our results showed that both isoforms significantly inhibited vascular epidermal growth 
factor (VEGF)-induced cell migration. Taken together, we have provided several lines of 
experimental evidence that two mouse ECSCR splicing variants/isoform precursors exist. 
They  are  differentially  expressed  in  a  variety  of  tissue  types  and  likely  involved  in 
modulation of vascular EC migration. We have also defined the gene structure of mouse 
ECSCR  using  bioinformatics  tools,  which  provides  new  information  towards  a  better 
understanding of alternative splicing of ECSCR.  
Keyword:  ECSCR/ECSM2;  alternative  splicing;  isoform;  gene  structure;  exon-intron 
boundary; cDNA cloning and expression; endothelial cell migration 
 
1. Introduction 
Angiogenesis or neovascularization is a physiological process by which new blood vessels develop 
from pre-existing vasculature [1]. It is not only fundamental for normal organ growth and development, 
wound healing, and female reproductive functions, but also critically involved in many pathological 
conditions,  such  as  ischemic  vascular  diseases,  atherosclerosis,  tumor  growth  and  metastasis, 
rheumatoid arthritis, diabetic retinopathies, and age-related macular degeneration [2–5]. Endothelial 
cells (ECs) constitute the inner layer of blood vessels and are the important players in angiogenesis, 
and EC migration is a key step during angiogenic process [6]. Thus, there has been a great deal of 
interest in identifying new genes specifically or preferentially expressed in vascular endothelial cells 
and studying their biological functions, which will help to develop more specific and effective pro- and 
anti-angiogenesis therapies.  
Over  the  past  several  decades,  massive  efforts  towards  this  direction  have  resulted  in  the 
identification of a number of important EC-specific or EC-highly expressed molecules, such as platelet 
endothelial  cell  adhesion  molecule  (PECAM-1  or  CD31)  [7],  vascular  endothelial  cell  adhesion 
molecule-1  (VCAM-1)  [8],  endothelial  cell-selective  adhesion  molecule  (ESAM)  [9],  vascular 
endothelial (VE)-cadherin (CD144 or cadherin 5) [10], vascular endothelial growth factor (VEGF) [11], etc. 
Newly developed bioinformatics strategies, such as database mining and virtual screening of public 
gene libraries, combined with transcriptional profiling (e.g., microarray and reverse transcription PCR) Int. J. Mol. Sci. 2012, 13  4922 
 
have been employed to ―clone‖ more novel EC-specific genes [12,13]. One of these important genes is 
human endothelial cell-specific molecule 2 (ECSM2) [14,15]. This gene has recently been described as 
apoptosis  regulator  through  modulating  cIAP  expression  (ARIA)  [16,17].  Currently,  its  approved 
nomenclature by the National Center for Biotechnology Information (NCBI) is endothelial cell-specific 
chemotaxis receptor (ECSCR) [18,19]. Despite its discovery about a decade ago, the biological and 
cellular functions of ECSCR/ECSM2/ARIA have only recently begun to be understood. Our laboratory 
is one of the two research groups who independently reported the molecular characteristics and cellular 
functions  of human ECSCR gene  [14,15].  Most  recently, we have demonstrated that  ECSCR  can 
localize  to  cell-cell  junction  and  modulate  basic  fibroblast  growth  factor  (bFGF)-directed  cell 
migration [20].  
Alternative splicing of pre-mRNA is a common posttranscriptional process utilized by eukaryotic 
organisms to generate multiple transcript variants from a single gene [21]. Alternatively spliced exons 
have splice sites that can be specifically recognized depending on tissue type, developmental stage, 
external stimuli, cellular stress, or pathological conditions [22]. Thus, alternative splicing has been 
considered as a major mechanism contributing to transcriptome and proteome complexity [23,24].  
In this study, we cloned two ECSCR full-length cDNA variants from mouse blood vessels, which 
likely encode two different hypothetical protein products of a single ECSCR gene. We named them 
ECSCR isoform-1 and isoform-2, respectively. Furthermore, we characterized the molecular structure 
and function of the two isoforms using combined bioinformatics and experimental approaches. 
2. Experimental Section 
2.1. Reagents and Antibodies 
Recombinant  human  VEGF  and  4',6-diamidino-2-phenylindole  dihydrochloride  (DAPI)  were 
purchased from Sigma (St. Louis, MO, USA). One kilobase DNA ladder and 1 kb Plus DNA ladder 
were obtained from Invitrogen (Carlsbad, CA, USA). All routine chemicals and reagents were from 
Sigma  or  Fisher  Scientific  (Pittsburgh,  PA,  USA)  unless  otherwise  noted.  Anti-GFP  polyclonal 
antibody and anti-FLAG monoclonal antibody M2 were obtained from Sigma. Tetramethyl Rhodamine 
Isothiocyanate  (TRITC)-conjugated  goat  anti-mouse  IgG  secondary  antibody  was  from  Jackson 
ImmunoResearch Laboratories (West Grove, PA, USA). Horseradish peroxidase (HRP)-conjugated 
goat  anti-rabbit and goat anti-mouse secondary antibodies were purchased from Pierce (Rockford,  
IL, USA). 
2.2. RNA Extraction, RT-PCR, and Quantitative Real-Time PCR 
Total RNAs were extracted from mouse large blood vessels (aorta) and other tissue types using 
TRIzol  Reagent  (Invitrogen).  cDNA  synthesis  was  performed  with  SuperScript  III  First-strand 
Synthesis Supermix (Invitrogen) and PCR was carried out using Pfu Ultra DNA polymerase (Agilent 
Technologies, Santa Clara, CA, USA). Quantitative PCR was performed using Platinum SYBR Green 
qPCR  Supermix  UDG  Kit  (Invitrogen)  on  the  iQ5  Real-Time  PCR  Detection  System  (Bio-Rad, 
Hercules, CA, USA). The mRNA level of ECSCR was normalized to that of the mouse housekeeping 
genes, β-actin and GAPDH, respectively. Int. J. Mol. Sci. 2012, 13  4923 
 
2.3. Plasmid Constructs and Sequencing 
Full-length cDNAs encoding mouse ECSCR isoform-1 and isoform-2 precursors, respectively, were 
obtained by RT-PCR and cloned into the expression vectors, pEGFP-N1 (Clontech Laboratories, Palo Alto, 
CA,  USA)  and  p3× FLAG-CMV-14  (Sigma),  respectively,  as  previously  described  [14,25,26].  These 
recombinant plasmid  constructs were  confirmed  by  sequencing, and  named pECSCR isoform-1-GFP, 
pECSCR isoform-2-GFP, pECSCR isoform-1-FLAG, and pECSCR isoform-2-FLAG, respectively. 
2.4. Cell Culture and Transfection 
Human kidney epithelial (HEK) 293 cells and mouse endothelial MS1 cells (both from ATCC, 
Manassas, VA, USA)  were grown in Dulbecco’s modified Eagle’s medium (DMEM)  (Mediatech, 
Manassas, VA, USA) containing 10% fetal bovine serum (FBS) (Sigma), 100 units/mL penicillin, and 
100 µg/mL streptomycin (both from Mediatech). Plasmid DNAs were transiently transfected into these 
two cell lines using Lipofectamine 2000 (Invitrogen), as described previously [14,25,26]. Transfection 
efficiency was confirmed by immunoblotting and/or immunofluorescent microscopy. The transfectants 
were subjected to various assays 48 h post transfection. 
2.5. Protein Extraction and Western Blot Analysis (Immunoblotting) 
Protein  extraction from  cells,  quantitation,  and  Western blot analysis (WB) were performed as 
described  elsewhere  [27–29].  Briefly,  cells  were  washed  once  with  ice-cold  phosphate-buffered  
saline (PBS) and then harvested by scraping in PBS followed by centrifugation. The cell pellets were 
lysed  and  solubilized  in  lysis  buffer  (50  mM  Tris-HCl  (pH  8.0),  2  mM  EDTA,  150  mM  NaCl,  
100 mM NaF, 10% glycerol, 1% SDS, 1 mM phenylmethylsulfony fluoride, 5 µg/mL aprotinin, and  
5  µg/mL  leupeptin).  The  cell  extracts  were  quantitated  with  bicinchoninic  acid  (BCA)  reagents 
(Pierce)  and  used  for  Western  blot  analysis  with  antibodies  as  specified  in  each  experiment. 
Immunoblotting  signals  were  detected  with  SuperSignal  chemiluminescent  substrate  (Pierce)  and 
digital images were captured using a Kodak 4000 MM molecular imager.  
2.6. Immunofluorescent Staining and Microscopy 
Cells  were  grown  on  glass  coverslips  precoated  with  gelatin  (2%)  and  fixed  in  4% 
paraformaldehyde for 15 min. When applicable, the cells were permeabilized with 0.25% Triton X-100 
in PBS containing 1% bovine serum albumin (BSA) for 15 min and stained with mouse anti-FLAG 
monoclonal antibody M2. The mouse antibody was detected with TRITC-conjugated goat anti-mouse 
IgG  secondary  antibody.  The  coverslips  were  mounted  onto  microscope  slides  in  Vectashield 
mounting medium for fluorescence containing DAPI (Vector Laboratories, Burlingame, CA). The cells 
expressing GFP alone or GFP fusion proteins were directly used for fluorescent visualization without 
antibody staining. Fluorescent images were captured with a Zeiss Axio Imager upright fluorescent 
microscope (Carl Zeiss, Thornwood, NY, USA), as described previously [20,25]. Int. J. Mol. Sci. 2012, 13  4924 
 
2.7. Cell Migration Assay 
MS1 cells were transiently transfected with pECSCR isoform-1-GFP, pECSCR isoform-2-GFP, or 
pEGFP-N1 (vector control) for 48 h. The transfectants were subjected to Transwell migration assay as 
described previously [20,28]. Briefly, BD Falcon 8 µm pore inserts (BD Biosciences, San Diego, CA, 
USA) were placed in a 12-well plate containing 1 mL of DMEM medium containing low serum (1% 
FBS) and VEGF (10 ng/mL) (lower chamber). Single cell suspensions (2.5 ×  10
5 cells in 0.5 mL of 
DMEM containing 1% FBS per well) were added to the upper chamber of each Transwell insert and 
incubated at 37 ° C for 5 h. At the end of incubation, the cells were fixed by submerging the Transwell 
inserts in 4% paraformaldehyde and counterstained with DAPI (0.5 μg/mL). The non-migrated cells on the 
top side of the membrane were removed with wet cotton swabs. Air dried membranes were cut out 
from the Transwell inserts, mounted onto microscope slides, and examined using a Zeiss Axio Imager 
upright fluorescent microscope (Carl Zeiss). The number of cells migrated across the membranes per 
imaging field was counted (n = 10 per condition). 
2.8. Statistical Analysis 
All statistical data were from multiple measurements as specified in each experiment and presented 
as  mean  ±  SD.  The significance of differences was  estimated using unpaired Student’s  t-test  and  
p < 0.05 was considered significant. 
2.9. Protein-Protein Basic Local Alignment Search Tool (BLASTP) 
The  full-length  protein  sequence  of  human  ECSCR  (205  amino  acids)  was  extracted  from  the 
GenBank via the NCBI website and used as a query sequence to blast the NCBI non-redundant protein 
sequences (nr), including all non-redundant GenBank CDS translations + PDB + SwissProt + PIR + PRF 
excluding  environmental  samples  from  whole  genome  shotgun  (WGS)  sequencing  projects,  using 
BLASTP 2.2.26+ program [30,31].  
2.10. Multiple Sequence Alignment 
Alignments  of  multiple  nucleotide  or  amino  acid  sequences  were  made  using  the  ClustalW2 
program via the EMBL-EBI website [32,33].  
2.11. Sequence Translation 
Translation of a DNA sequence to a protein sequence was performed using the ExPASy Translate 
tool [34]. 
2.12. Prediction of Signal Peptide and Transmembrane Domain 
Prediction of signal peptide was made using several web-based programs including SIG-Pred [35], 
PrediSi [36], and SignalP 4.0 [37]. Transmembrane domain was predicted using the Transmembrane 
Prediction Server (DAS) [38,39]. Int. J. Mol. Sci. 2012, 13  4925 
 
2.13. Prediction of Glycosylation Sites 
Putative N-glycosylation and O-glycosylation sites were predicted using NetNGlyc 1.0 Server [40] and 
NetOGlyc 3.1 server [41,42], respectively. 
3. Results and Discussion 
In our previous study, we identified a number of hypothetical proteins across species exhibiting 
substantial sequence homology to the human ECSCR/ECSM2 (GenBank acc No. NP_001071161), 
one of which is mouse ECSCR (GenBank acc No. NP_001028313) [14]. To explore the possibility of 
existence of multiple isoforms of ECSCR, here we performed a protein-protein blast search (BLASTP) 
on  non-redundant  protein  sequences  using  the  205-amino  acid  human  ECSCR  (Swiss-Prot  acc  
No. Q19T08) as a query sequence. Interestingly, we obtained two hits from the mouse species. One is 
annotated as ECSCR/ECSM2 (GenBank acc No. NP_001028313.1), as expected, and the other one is 
RIKEN cDNA 1110006O17 (GenBank acc No. EDK97141.1). We noticed that the two hypothetical 
proteins only differ in the first 30–35 amino acids at their N-termini. Given that the mouse ECSCR 
sequence  with  GenBank  acc  No.  NP_001028313.1  [43]  has  been  reported  in  several  recent  
literatures [14,16,17,19,44,45], here we designated it as ECSCR isoform-1 precursor and the RIKEN 
cDNA 1110006O17 (GenBank acc No. EDK97141.1) as isoform-2 precursor, respectively. Based on 
the  available  information  of  their  corresponding  nucleotide  sequences  in  the  NCBI  databases,  we 
designed specific primers for both isoforms and obtained full-length of cDNAs by RT-PCR using total 
RNAs extracted from mouse large blood vessels (aorta) (Figure 1). The open reading frames of the two 
cDNAs  and  their  alignment  results  are  shown  in  Figures  S1–S3.  The  coding  regions  of  the  two 
transcripts are nearly identical except for the initial ~100 bp segments (Figure S3), suggesting that they 
are alternative splicing variants. 
Alignment of amino acid sequences of human ECSCR and the two mouse isoform precursors is 
displayed in Figure 2A. We also performed structure prediction using the ExPASy proteomic tools [46]. 
The  results  indicated  that,  similar  to  the  human  ECSCR,  both  mouse  isoforms  are  most  likely 
membrane  proteins,  each  containing  a  long  N-terminal  extracellular  domain  (ECD),  a  single 
transmembrane domain (TM), and a short intracellular domain (ICD) at the C-terminus (Figure 2A). 
Using  the  SIG-Pred  (Signal  Peptide  Prediction)  program  [35],  the  human  ECSCR  and  the  mouse 
ECSCR isoform-2 precursors were predicted to contain a signal peptide (SP) of 24 and 39 amino acid 
residues at their respective N-terminus with a high score (Figure 2A). In contrast, no signal peptide 
was predicted for the mouse isoform-1 precursor due to an extremely low score. Similar results were 
obtained when other signal peptide prediction programs, such as PrediSi [36] and SignalP 4.0 Server [37], 
were employed. Furthermore, we used NetNGlyc 1.0 Server [40] and NetOGlyc 3.1 server [41] to 
search for potential N-glycosylation sites (Asn-Xaa-Ser/Thr sequons) and mucin-type O-glycosylation 
Ser/Thr  sites,  respectively.  The  human  ECSCR  has  a  putative  N-glycosylation  site  within  its  
N-terminal ECD whereas no N-glycosylation site was found in the two mouse ECSCR sequences 
(Figure  2A).  In  contrast,  a  number  of  potential  O-glycosylation  sites  were  identified  in  all  three 
ECSCR proteins as indicated in Figure 2A. We also noted that the predicted O-glycosylation sites of Int. J. Mol. Sci. 2012, 13  4926 
 
mouse ECSCR isoform-1 slightly differ from those of isoform-2 (Figure 2A). The sequence homology 
(identify and similarity) among these proteins is shown in Figure 2B. 
Figure 1. RT-PCR to obtain full-length cDNAs encoding mouse ECSCR isoform-1 and 
isoform-2 precursors. Total RNAs were extracted from mouse large blood vessels (aorta) 
and  RT-PCR  was  performed  to  obtain  full-length  cDNAs  that  encode  mouse  ECSCR 
isoform-1 (A) and isoform-2 (B), respectively. DNA ladders are shown. 
 
Figure 2. Identification of mouse ECSCR isoform-1 and isoform-2 precursors. (A) Amino 
acid  sequence  alignment  of  mouse  ECSCR  isoform-1,  isoform-2,  and  human  ECSCR 
precursors.  Putative  signal  peptides  (SP)  are  underlined  and  a  single  transmembrane 
domain (TM) is boxed. Predicted N-glycosylation and O-glycosylation sites are shown in 
red and blue, respectively. (B) Percentages of identity and similarity among the amino acid 
sequences of mouse ECSCR isoform-1, isoform-2, and human ECSCR precursors. 
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To  further  define  the  gene  structure  encoding  the  two  mouse  ECSCR  isoform  precursors,  we 
examined the mouse genome sequences and successfully mapped the two cDNAs/transcripts within 
the region from 19601084 to 19610340 of Mus musculus 181000113601716 genomic scaffold, whole 
genome shotgun sequence [47]. We identified a total of 10 exons, of which Exon 1 is spliced out in 
isoform-1  and  Exon  2  is  spliced  out  in  isoform-2  (Figure  3).  The  updated  mouse  ECSCR  gene 
sequences are presented in Figure S4, in which all ten exons and exon-intron boundaries are marked. 
We noted that in the current public annotation for mRNA product ―RIKEN cDNA 1110006O17‖ 
(referred to as isoform-2 here) [47], only nine exons are defined, which do not include the definition of 
Exon 2. Our results clearly indicated that the mouse ECSCR isoform-1 and isoform-2 precursors are 
indeed splicing variants from a single ECSCR gene. 
Figure  3.  Gene  structure  of  mouse  ECSCR  and  alternative  splicing  events.  The 
reconstructed mouse ECSCR gene is based on new data presented in this study. A total of 
ten exons are indicated by closed boxes. 
 
We next sought to compare the expression patterns of the two splicing variants in a variety of 
mouse cell lines and tissues by quantitative real-time RT-PCR (qRT-PCR). As shown in Figure 4A,B, 
when normalized to the expression level of a housekeeping gene (β-actin), both ECSCR isoform-1 and 
isoform-2 were highly expressed in the mouse EC line (MS1) but not in the non-EC lines (C2C12 and 
3T3-F442A)  tested  here.  Noticeably,  however,  the  abundance  of  transcripts  of  isoform-2  was 
approximately 200 fold of that of isoform-1 (Figure 4B), suggesting that isoform-2 is the predominant 
form expressed in mouse ECs. Furthermore, our qRT-PCR results indicated that both isoforms were 
differentially  expressed  among  a  variety  of  tissues  examined  here  (Figure  5).  The  transcripts  of 
isoform-2 were most abundant in heart, lung, and muscles, and moderately abundant in uterus and 
testis. Surprisingly, its expression level in the above-mentioned tissues was higher than that in large 
blood vessels (aorta) (Figure 5A). As for isoform-1, its transcripts were found to be relatively high in 
testis, muscles, and large blood vessels (Figure 5B). Regardless of the tissue types, in general, the 
expression  level  of  isoform-2  mRNA  was  much  higher  than  that  of  isoform-1.  For  example,  the 
abundance of isoform-2 transcripts was ~150 fold of that of isoform-1 in muscles and ~50 fold in large 
blood  vessels  (aorta).  Similar  results  were  obtained  when  the  expression  levels  of  isoform-1  and Int. J. Mol. Sci. 2012, 13  4928 
 
isoform-2 mRNA were normalized to another  commonly used housekeeping gene,  glyceraldehyde  
3-phosphate dehydrogenase (GAPDH) (data not shown). 
Figure 4. Expression of ECSCR isoform-1 and isoform-2 in cultured mouse cell lines.  
(A) The mRNA levels of isoform-1 and isoform-2 measured by qRT-PCR. C2C12, mouse 
myoblasts; 3T3-F442A, mouse preadipocytes; MS1, mouse endothelial cells. (B) The ratio 
of  mRNA  level  of  isoform-2  to  that  of  isoform-1  indicates  that  isoform-2  is  the 
predominant form expressed in endothelial MS1 cells. Data are mean ±  SD (n = 3). 
 
ECs  line  the  circulatory  system,  including  the  heart,  arteries,  veins  and  capillaries.  It  is  now 
recognized that ECs have important physiological functions not only for the circulatory system but 
also  for  different  organs  that  the  blood  vessel serve.  In  general,  ECs  can  be  classified  into  three 
categories, including continuous ECs, fenestrated ECs, and discontinuous ECs. The continuous ECs 
occur in all major blood vessels and capillaries of the lung, heart, muscles, and brain. These ECs are 
connected by a series of cell-cell junctions. The fenestrated ECs are found in the gastrointestinal villi, 
glomeruli  of  kidneys  and  in  capillaries  that  supply  the  endocrine  glands.  Their  cell  junctions  are 
similar  to  those  of  continuous  endothelium,  but  the  presence  of  fenestrate  occurs.  In  contrast, 
discontinuous ECs are not connected to each other and are often interspersed by another type of cells. 
The capillaries with discontinuous ECs are known as sinusoidal capillaries, which occur in bone marrow, 
the spleen and the liver. Thus, the current discovery of higher expression level of ECSCR isoform-2 in 
the heart, lung, muscles, uterus, and testis than in large blood vessels (Figure 5A) could suggest that 
isoform-2 is preferentially expressed in capillaries consisting of continuous ECs. Interestingly, this is 
consistent with our recent findings that ECSCR is a novel EC junctional protein [20]. Based on our 
experimental results shown in Figures 4 and 5, we concluded that isoform-2 is probably the most 
common form of ECSCR splicing variants identified so far in the mouse species and it is highly 
expressed in continuous endothelium (more dominant in capillaries than in large vessels). However, 
the relatively high abundance of isoform-1 detected in the testis compared to other tissue types may 
have its biological and pathological significance, which deserves further investigation in the future. Int. J. Mol. Sci. 2012, 13  4929 
 
Figure 5. Expression of ECSCR isoform-1 and isoform-2 in a variety of mouse tissues. 
The mRNA levels  of isoform-2 (A)  and isoform-1 (B) measured by qRT-PCR. Blood 
vessels examined here were large vessels (aorta). Data are mean ±  SD (n = 3). 
 
To further characterize the two mouse ECSCR isoforms at the cellular level, we heterologously 
expressed both isoforms tagged with either green fluorescent protein (GFP) or FLAG at their C-termini 
in human embryonic kidney (HEK) 293 cell line that does not endogenously express ECSCR [14]. 
Similarly  to  what  we  have  previously  reported  for  human  ECSCR  [14,20],  immunoblotting  with  
anti-GFP (Figure 6A) and anti-FLAG (Figure 6B) antibodies, respectively, indicated that the molecular 
mass  of  both  isoform-1  and  isoform-2  was  markedly  larger  than  their  corresponding  predicted  
sizes (Figure 6C). This suggested that glycosylation may occur during the protein process for both 
isoforms  in  vivo,  as  we  demonstrated  previously  for  human  ECSCR  [14,20].  Notably,  the  actual 
molecular mass of the mouse ECSCR isoform-1-GFP or isoform-1-FLAG was slightly larger than that 
of  isoform-2-GFP  or  isoform-2-FLAG  on  SDS-PAGE  (Figure  6A,B).  This  could  be  due  to  the 
different predicted O-glycosylation sites of the two isoforms and/or the absence of a predicted signal 
peptide in isoform-1 precursor (Figure 2A). Furthermore, like human ECSCR-GFP, both isoform-1-GFP 
and isoform-2-GFP proteins clearly displayed plasma membrane localization, revealed by fluorescence 
microscopy  (Figure  7A).  In  particular,  immunofluorescent  staining  using  an  anti-FLAG  antibody 
demonstrated  that  membrane-bound  mouse  ECSCR  isoform-2-FLAG  was  detected  only  in  Int. J. Mol. Sci. 2012, 13  4930 
 
detergent-permeabilized cells  but  not  in  nondetergent-treated cells  (Figure 7B), indicating that the  
C-terminus of ECSCR is located in the cytosol. All these results are consistent with our molecular 
prediction (Figure 2A).  
Figure 6. Heterologous expression of mouse ECSCR isoform-1 and isoform-2 proteins 
suggests that they are likely glycoproteins. (A and B) GFP- or FLAG-tagged human (h) 
ECSCR, mouse isoform-1, and isoform-2 were expressed I HEK293 cells, respectively. 
The expression of  fusion proteins  was confirmed by Western blot  (WB)  analysis with  
anti-GFP  (A)  or  anti-FLAG  (B)  antibody.  The  glycosylated  (mature)  forms  of  fusion 
proteins are indicated by asterisks. (C) Comparison of the actual molecular weights (MW) 
of the fusion proteins in kilodaltons (kDa) on SDS-PAGE with their predicted molecular 
weights (MW) based amino acid sequences. 
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Figure  7.  Cell  surface  localization  of  mouse  ECSCR  isoforms.  (A)  HEK293  cells 
expressing  GFP  alone,  human  (h)  ECSCR-GFP,  mouse  ECSCR  isoform-1-GFP,  and 
isoform-2-GFP, respectively, were visualized by fluorescent microscopy. Scale bar, 50 µm. 
(B)  Mouse  ECSCR  isoform-2  tagged  with  FLAG  at  its  C-terminus  was  expressed  in 
HEK293 cells and the transfectants were costained with anti-FLAG antibody and DAPI. 
The cell surface localization of ECSCR-FLAG was detected only in the cells that were 
permeabilized with 0.1% Triton X-100. Scale bar, 20 μm. 
 
Finally, we explored the potential cellular functions of the two mouse ECSCR isoforms. Here, we 
used a similar strategy as described previously for human ECSCR [14,20], and assessed VEGF-driven 
cell migration (chemotaxis) in MS1 cells overexpressing GFP alone, mouse ECSCR isoform-1-GFP, 
and isoform-2-GFP, respectively. As previously shown, overexpression of GFP in MS1 cells did not 
affect  cell  migration  [20],  which  served  as  a  control  in  the  migration  assays.  In  a  representative Int. J. Mol. Sci. 2012, 13  4932 
 
experiment  shown  in  Figure  8,  overexpression  of  either  mouse  ECSCR  isoform-1-GFP  or  
isoform-2-GFP in MS1 cells significantly attenuated VEGF-induced cell motility compared to the GFP 
control cells. This is in agreement with our previous conclusion that overexpression of human ECSCR 
inhibits  cell  migration  mediated  by  growth  factors  such  as  epidermal  growth  factor  (EGF)  [14]  
and bFGF [20]. 
Figure 8. Overexpression of mouse ECSCR isoforms in MS1 cells inhibits endothelial cell 
motility.  MS1  cells  overexpressing  GFP  alone,  mouse  ECSCR  isoform-1-GFP,  and 
isoform-2-GFP, respectively, were subjected to Transwell migration assay, in which VEGF 
(10 ng/mL) was used as a chemoattractant as detailed in Methods. The cells were allowed 
to migrate for 5 h. The number of migrated cells per imaging field for each condition was 
counted. Data are mean ±  SD (n = 10), * p < 0.05, ** p < 0.01. 
 
We and other groups have demonstrated that both human ECSCR and mouse ECSCR are critically 
involved in the modulation of EC migration, a key step during angiogenic process [14,15,17,18,20] 
(and  this  study).  However,  the  existing  data  regarding  ECSCR  functioning  in  EC  motility  and 
endothelial  tube  formation  on  Matrigel  (in  vitro  angiogenesis)  have  shown  some  discrepancy. 
Armstrong et al. reported that siRNA knockdown of ECSCR in human umbilical vein endothelial cells 
(HUVECs)  inhibited  EC  migration  when  fetal  calf  serum  (FCS)  and  endothelial  cell  growth 
supplements  (TCS)  together  were  used  as  the  chemoattractant  and  impaired  tube  formation  [15]. 
Verma et al. showed that knockdown of ECSCR in HUVECs resulted in reduced migration in response 
to fetal bovine serum (FBS) or VEGF [18]. In contrast, our gain or loss of function assays showed that 
overexpression  or  knockdown  of  human  ECSCR  in  ECs  attenuated  or  enhanced  bFGF-directed 
migration, respectively [20]. Our early work also revealed that coexpression of human ECSCR and 
EGF receptor (EGFR) in HEK293 cells inhibited EGF-induced cell motility [14]. In the current study, 
we extended our findings to mouse homologues of ECSCR including two isoforms. Consistent with 
our previous findings, overexpression of either mouse ECSCR isoform-1 or isoform-2 in MS1 cells 
resulted in reduced cell migration driven by VEGF. Interestingly, Ikeda et al. initially observed that 
knockdown of ARIA/ECSCR in HUVECs by siRNA reduced endothelial apoptosis without affecting Int. J. Mol. Sci. 2012, 13  4933 
 
cell migration [16]. However, in  vivo angiogenesis, which was studied using Matrigel-plug assay, 
mouse  ischemic  retinopathy  model,  and  tumor  xenograft  model,  was  significantly  enhanced  by 
ARIA/ECSCR  knockdown  [16].  More  recently,  the  work  from  the  same  group  demonstrated  that 
siRNA-mediated silencing of ARIA/ECSCR in  cord blood  late outgrowth ECs  (OECs) attenuated 
apoptosis and accelerated migration towards stromal cell-derived factor-1α (SDF-1α), and re-expression 
of ARIA (ECSCR) reversed the effects of siRNA silencing on apoptosis and migration [17]. They pointed 
out that the different effects of ARIA/ECSCR knockdown on cell motility from their two studies was 
probably  due  to  the  insufficient  silencing  in  HUVECs  (~60%  reduction  in  mRNA)  versus  nearly 
complete  knockout  in  OECs  (~98%  reduction  in  mRNA)  [17].  Nevertheless,  their  later  study 
confirmed that ECs isolated from ARIA/ECSCR knockout mouse aorta exhibited reduced apoptosis 
and accelerated motility and tube formation [17]. Although it is not clear whether ECSCR isoform-1, 
isoform-2 or both were knocked out in their mice (generated by targeted deletion of the first three 
exons  of  the  gene  [17]),  this  piece  of  elegant  work  at  least  suggests  that  mouse  ECSCR  has  an  
anti-angiogenic  rather  than  a  pro-angiogenic  effect.  Apparently,  our  previous  and  current  in  vitro 
results strongly support such an opinion. 
4. Conclusions 
In this study, we have provided several lines of experimental evidence that two mouse ECSCR 
splicing variants (isoform-1 and isoform-2) exist, which are differentially expressed in a variety of 
tissue types and likely involved in the modulation of vascular EC migration. We have also defined the 
gene structure of mouse ECSCR using bioinformatics tools, which provides new information towards a 
better  understanding  of  alternative  splicing  of  ECSCR.  The  exact  functions  and,  in  particular, 
differential functions of the two isoforms deserve further investigation. This may require successful 
generation of specific antibodies targeting different ECSCR isoforms, which could be a new challenge 
in the field. 
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